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ABSTRACT
Expression of type 5 phosphodiesterase (PDE5), a cGMP-specific hydrolytic 
enzyme, is frequently altered in human cancer, but its specific role in tumorigenesis 
remains controversial. Herein, by analyzing a cohort of 69 patients affected by 
glioblastoma multiforme (GBM) who underwent chemo- and radiotherapy after 
surgical resection of the tumor, we found that PDE5 was strongly expressed in 
cancer cells in about 50% of the patients. Retrospective analysis indicated that high 
PDE5 expression in GBM cells significantly correlated with longer overall survival 
of patients. Furthermore, silencing of endogenous PDE5 by short hairpin lentiviral 
transduction (sh-PDE5) in the T98G GBM cell line induced activation of an invasive 
phenotype. Similarly, pharmacological inhibition of PDE5 activity strongly enhanced 
cell motility and invasiveness in T98G cells. This invasive phenotype was accompanied 
by increased secretion of metallo-proteinase 2 (MMP-2) and activation of protein 
kinase G (PKG). Moreover, PDE5 silencing markedly enhanced DNA damage repair 
and cell survival following irradiation. The enhanced radio-resistance of sh-PDE5 GBM 
cells was mediated by an increase of poly(ADP-ribosyl)ation (PARylation) of cellular 
proteins and could be counteracted by poly(ADP-ribose) polymerase (PARP) inhibitors. 
Conversely, PDE5 overexpression in PDE5-negative U87G cells significantly reduced 
MMP-2 secretion, inhibited their invasive potential and interfered with DNA damage 
repair and cell survival following irradiation. These studies identify PDE5 as a favorable 
prognostic marker for GBM, which negatively affects cell invasiveness and survival to 
ionizing radiation. Moreover, our work highlights the therapeutic potential of targeting 
PKG and/or PARP activity in this currently incurable subset of brain cancers.
INTRODUCTION
Astrocytic brain tumors are divided into low-grade 
and high-grade astrocytomas on the basis of specific 
parameters established by the WHO (presence or absence 
of nuclear atypia, mitosis, necrosis and angiogenesis). 
Low-grade tumors comprise pilocytic astrocytomas (grade 
I), fibrillary, protoplasmic and gemistocytic astrocytomas 
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(grade II), whereas anaplastic astrocytoma (grade III) and 
glioblastoma multiforme (GBM; grade IV) are classified 
as high-grade tumors [1, 2]. Although the cell of origin 
for glioma is still under debate, good candidates are NSCs 
or NSC-derived astrocytes or oligodendrocyte precursor 
cells (OPCs) [3]. GBM is the most common and fatal 
type of primary brain tumors, with annual incidence of 
about 3.19 cases per 100,000 in the population. Most 
patients survive approximately 1 year, and only 5% live 
for more than 5 years [1, 4]. GBM develops de novo by 
accumulation of genetic alterations in healthy cells [1], 
however, accumulation of additional genetic lesions in 
low-grade tumors can also determine their evolution to 
secondary GBM. Standard treatment for GBM consists 
of maximal surgical resection followed by 6 weeks of 
radiotherapy, plus concomitant adjuvant chemotherapy 
with temozolomide (TMZ) [5]. Prognostic factors for 
overall survival (OS) include patient status, tumor grade, 
and type of oncological treatment [6]. Methylation status 
of the O(6)-methylguanine-DNA methyltransferase 
(MGMT) gene promoter [7], mutations in the isocitrate 
dehydrogenase 1 (IDH1) and 2 (IDH2) genes [8] and 
epidermal growth factor receptor (EGFR) amplification or 
truncation (EGFRvIII) are considered additional molecular 
markers of prognostic value [9].
PDE5 is a cGMP-specific hydrolytic enzyme 
that has been extensively studied as it is the target of 
widely prescribed erectile dysfunction drugs (sildenafil, 
vardenafil, tadalafil and avanafil). The PDE5A gene 
maps at human chromosome 4q26 and encodes three 
alternatively spliced isoforms differing in their first exon 
[10, 11]. PDE5A transcripts are expressed in several tissues 
and cell types, including smooth muscle, cerebellum, 
retina and platelets [10]. Within the brain, PDE5 has been 
reported to be expressed within the hippocampus cortex, 
basal ganglia, cerebellum and in neural stem cells (NSC) 
[12–14]. Conflicting data have been reported on the role 
of PDE5 in cancer. PDE5 is expressed in several tumor 
types, such as breast, colon, bladder and lung carcinomas 
[15] and its inhibition was shown to enhance the cytotoxic 
effects of chemotherapy in prostate cancer and in murine 
and human brain tumor models [16–18]. By contrast, a 
negative correlation between PDE5 expression and tumor 
invasiveness was observed in metastatic melanoma [19, 
20], a cancer type of neuro-ectodermal origin. In particular, 
it was shown that BRN2, a V600EBRAF activated target, 
represses PDE5 expression, thus increasing spreading of 
metastases. In support of this finding, it was reported that 
patients treated with sildenafil exhibited a higher risk of 
developing melanoma than untreated subjects [21]. PDE-
mediated hydrolysis of intracellular cGMP is balanced by 
guanylate cyclase enzymes (GCs). Increased cGMP levels 
activate the PKGs and their downstream effectors [22]. 
Interestingly, the nitric oxide (NO)/cGMP/PKG system has 
been proposed to be involved in GBM stem cell expansion 
[23] and high levels of cGMP, as well as treatment with 
sildenafil, strongly enhance mouse GBM cancer stem 
cell phenotype in vitro and their tumorigenic potential 
in vivo [23]. In this study, we explored the prognostic 
value of PDE5 in GBM patients and investigated whether 
modulation of PDE5 function influences GBM cell 
invasiveness and resistance to radiotherapy.
RESULTS
PDE5 expression positively correlates with 
overall survival rates in primary GBMs
To assess the value of PDE5 expression as molecular 
prognostic marker for GBM, we analyzed its levels in 
tumor sections obtained from 69 patients who underwent 
radiotherapy and TMZ treatment following surgical 
resection. In about 50% of these patients we found a 
strong PDE5 immuno-reactivity (score 4-9) in cancer 
cells. With the exception of vascular smooth muscle cells, 
PDE5 was not expressed in the unaffected surrounding 
tissue. The remaining 50% of cases showed low or no 
PDE5 immuno-staining in the tumor, while positivity was 
still found in the vascular structures (Figue 1A-1D). Next, 
we examined the associations of PDE5 expression with the 
clinical outcome of patients followed for a median period 
of 40 months (range= 2–50 months). Retrospective data 
analysis showed that high PDE5 expression in tumor cells 
strongly correlated with an increased OS (15 months vs 
10 months, p=0,0028; Figure 1E). Multivariate analyses 
including EGFRvIII expression, age, KI67 index, KPS, 
MGMT status (Figure 1F) and PDE5A expression showed 
that MGMT status (p=0,022) and PDE5A (p=0,0046) 
expression are independent prognostic factors in GBM. 
With respect to other clinical and biological characteristics, 
only EGFRvIII expression was inversely correlated with 
PDE5 positivity in GBM patients, as evaluated by Fisher 
exact test (p=0. 0306; HR 0.3230; 95% CI from 0.1209 
to 0.8630). The extent of resection (total vs subtotal) did 
not influence the OS and did not correlate with PDE5 
expression in the tumor mass.
We then assessed the OS in two different cohorts 
of GBM patients from publicly available gene expression 
datasets [24, 25]. As shown in Figure 2A and 2B we found 
that high PDE5 mRNA levels are significantly associated 
with a longer OS as compared to low PDE5 mRNA levels. 
In agreement, we also found that recurrent tumors showed 
lower PDE5 mRNA levels compared to primary tumors 
(Figure 2C). Moreover, performing an expression analysis 
of cell lines derived from primary and recurrent GBM with 
resistance to the O(6)-alkylating agents bis(chloroethyl)
nitrosourea (BCNU) and TMZ [26], we found that cell 
lines obtained from recurrent gliomas showed lower PDE5 
mRNA expression (Figure 2D). Altogether these results 
suggest that PDE5 expression plays a protective role in 
GBM.
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Figure 1: PDE5 expression correlates with OS in GBM. A. PDE5 negative and B. PDE5 positive GBM samples, as revealed 
by immuno-histochemistry. Red arrow points to positive cancer cells, black arrows point to positive vascular smooth muscle cells. Scale 
bar=50μm, 100X magnification. PDE5 and smooth muscle actin (SMA) expression in smooth muscle cells in a PDE5 negative C. and in 
a PDE5 positive D. GBM sample. Scale bar=10μm. E. Kaplan–Meier curves representing the OS of 69 patients affected by GBM, (PDE5 
positive, blue circles; PDE5 negative, red squares) after TMZ and X-ray treatments. F. The hazard ratios and 95% confidence intervals were 
calculated using a multivariable-adjusted Cox model, and the p values were calculated using a two-sided log-rank test.
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cGMP generating/hydrolytic pathways in GBM 
cell lines
To understand how PDE5 expression might affect 
GBM cells, we first analyzed its expression levels in 
five GBM cell lines and in a GBM stem cell line (line 
83). Strikingly, we found that only T98G cells expressed 
high levels of PDE5, along with PDE1C, but not PDE1A 
and PDE3A, that represent other phosphodiesterases 
specific for cGMP hydrolysis (Supplementary Figure 
1A-1D), while PDE6 and PDE11 were not expressed 
(not shown). PDE5 localized diffusely throughout the 
cell, but it was particularly concentrated in centrosomes 
[27] (Supplementary Figure 1B). We found that all the 
glioblastoma cell lines but A172 cell line expressed 
GUCY1A2, GUCY1A3, GUCY1B3, the subunits of the 
the dimeric soluble GC receptor activated by NO, as well 
as NPR2, the receptor-coupled GC isoform that binds 
C-type natriuretic peptide (CNP) (Supplementary Figure 
1E). To understand if T98G cell line was responsive to 
these ligands, we stimulated the scrambled cells with 
1μM S-nitrosoglutathione (GSNO, a synthetic nitric oxide 
donor) or 1μM type C natriuretic peptide (CNP) for 15 
min. Either GSNO or CNP induced a consistent increase 
Figure 2: Clinical association of PDE5A gene expression with survival of GBM patients from public datasets. A. The 
association between expression levels of PDE5A and OS was evaluated by Kaplan–Meier analysis B. and gene expression analysis to 1 
year by box-plot graph, respectively in two public datasets [24, 25] (56 and 21 patients, respectively). Statistically significant results (p-
value < 0.05) are indicated. The hazard ratios and 95% confidence intervals were calculated using a multivariable-adjusted Cox model, and 
the p values were calculated using a two-sided log-rank test. C. PDE5A expression levels from 25 GBM patients obtained from the public 
dataset of Liang et al. [24]. Casuistry samples have been divided between «primary occurrence» (18 patients) and «recurrence» (7 patients). 
PDE5A mRNA expression levels in these samples are reported in the box-plot. A statistically significant correlation is shown between PDE5 
mRNA low levels and the GBM's relapse. D. PDE5A expression analysis of cell lines derived from primary (7) and recurrent glioblastomas 
(8) with resistance to O(6)-alkylating agents, BCNU and TMZ is shown as box plot graph. The expression values are processed by the 
public repository dataset of Bredel et al. [55].
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of intracellular cGMP levels (18 ± 3.6pmol/mg and 
21±2.2pmol/mg, respectively) compared to control cells 
(2.35±0.6 pmol/mg), while sildenafil, slightly increased 
cGMP levels (3.5± 1.7pmol/mg) (Supplementary Figure 
1F). Stimulation of T98G with both GSNO and sildenafil 
or with CNP and sildenafil strongly amplified the effect 
on cGMP levels (95±8.5pmol/mg and 102± 6.6pmol/mg, 
respectively). Moreover, sildenafil treatment alone was 
able to increase cGMP levels compared to the control 
(2.5±0.05pmol/mg and 80±3.5pmol/mg, respectively), 
after an overnight stimulation. Similarly to smooth muscle 
cells (S.D., unpublished observations) [28], PDE5 protein 
levels were up regulated in T98G by the presence of 5 
μM MAP kinase inhibitors PD98059 or U0123, while they 
were down regulated by 10 ng/ml EGF. In the presence of 
both PD98059 and EGF, PDE5 levels were almost restored 
to the control levels (Supplementary Figure 1G, 1I). 
Interestingly, both GSNO and CNP independently induced 
Erk1/2 phosphorylation following 3 h of stimulation 
(Supplementary Figure 1H, 1L), suggesting that also PKG 
was activating the MAPK pathway.
Effect of PDE5 knockdown on GBM cell growth, 
migration and invasiveness
We chose T98G, U87MG and line 83 cells as in 
vitro models to silence or over-express PDE5 by using sh-
PDE5 or over-expressing lentiviral particles, respectively 
(Supplementary Figure 2A-2B). As expected, cGMP levels 
were up-regulated after knockdown of PDE5 in T98G 
that have been silenced with two different sh-lentiviral 
particles (sh1 and sh2) and down-regulated in U87MG and 
line 83 cells overexpressing PDE5 (Supplementary Figure 
S2), confirming that modulation of PDE5 expression by 
these approaches was functionally relevant. MTS and 
H3-thymidine incorporation assays indicated that PDE5 
knockdown or over-expression did not affect proliferation 
and survival of GBM cell lines (Supplementary Figure 
2F-2H). To investigate if PDE5 expression affects GBM 
cell migration and invasiveness, we performed wound-
healing and matrigel invasion assays in T98G cells. 
Wound-healing tests showed that sh1 or sh2-PDE5 T98G 
cells completely filled the gap area created by a scratch 
following 24 h of culture (100%), whereas control sh-scr 
cells only covered about 48.4% of the wound. Importantly, 
PDE5 inhibition with 1 μM sildenafil (70%) or 100 μM 
8br-cGMP also increased the wound-healing ability of sh-
scr cells (78%), whereas these agents did not affect the 
invasive behavior of cells that were already silenced for 
PDE5 (Figure 3A-3B).
Next, we tested whether PDE5 expression also 
affected GBM cell invasion. Sh-scr or sh1-PDE5 T98G 
cells were layered on top of matrigel cushions and the 
percentage of cells that passed through pores of filter 
membranes or reached the multiwell bottom was evaluated 
after 24 h (Figure 3C-3D and 4G, respectively). We 
observed that sh1-PDE5 cells were able to pass through 
the membrane pores, while sh-scr cells were always 
found on top of the matrigel cushion (10 fold increase 
in sh1-PDE5 vs sh-scr T98G cells). Sildenafil treatment 
strongly increased cell migration in both sh-scr or sh1-
PDE5 T98G (5 fold increase and 2.2 fold increase vs 
untreated control, respectively). The increase in the 
number of migrating cells was even stronger after 8br-
cGMP treatment (20 fold in sh-scr T98G cells vs untreated 
control and 2.1 fold in sh1-PDE5 T98G cells). In line with 
a negative role of PDE5 in the regulation of GBM cell 
migration, overexpression of PDE5 in PDE5-negative 
U87MG or GBM line 83 cells completely blocked their 
ability to migrate through the membrane after 24 h of 
culture (Figure 3E-3F). These results strongly indicate 
that high cGMP levels stimulate GBM cell motility and 
invasiveness.
To investigate whether the increased cell 
invasiveness correlated with metastasis-associated 
MMP secretion, the levels of MMP-2 and MMP-9 
were measured in cell-culture supernatants from sh-
scr or sh1-PDE5 T98G cells and from mock- or PDE5-
overexpressing U87MG by gelatin zymography. We 
found that MMP2 levels were significantly induced in 
the supernatant of sh1-PDE5 T98G compared to sh-
scr cells (Figure 3G; P=0.005) and reduced in U87MG 
overexpressing PDE5 compared to their controls (Figure 
3H; P=0.005). We found that MMP-2 secretion by T98G 
sh-scr was also stimulated by other cGMP inducing agents 
such as CNP (1μM), GSNO (1μM) or sildenafil treatments 
(Figure 3I). MMP-9 was barely detectable in T98G cells 
in the conditions used to evaluate the activity of MMP-2, 
while we did not find any change in its levels in U87MG 
cells (not shown).
PKG regulates GBM invasiveness
cGMP modulates cytoskeletal interactions through 
PKG activation [29, 30]. We then investigated if PKG1 
was expressed in glioblastoma samples by IHC. Thirty 
GBM samples (15 with high and 15 with low or null 
PDE5 levels) were analyzed. We found that PKG1 was 
expressed in all the GBM samples (Figure 4A), although 
with different level of intensity, that were not significantly 
correlated to PDE5 expression. PKG1 was localized in 
glioblastoma cells and in the smooth muscle wall of tumor 
vessels. We found that PKG1α PKG1β and PKGII isoforms 
were all expressed in the different GBM cell lines. To 
understand if PKG activation by cGMP was involved in 
cell invasion, we performed invasion assays in the presence 
of the pan-PKG inhibitor KT5823 (2 μM). As expected, 
8br-cGMP treatment or PDE5 knockdown stimulated 
T98G cell migration. Importantly, KT5823 was able to 
inhibit both basal and 8br-cGMP-induced cell motility in 
T98G sh-scr and in PDE5 silenced cells (Supplementary 
Figure S3). PKG phosphorylates Ser695 of the myosin 
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Figure 3: Effect of PDE5 knockdown or overexpression on cell migration and invasion in vitro. A. Wound healing assay and 
B. Histogram showing the mean percentage ±SD of closure of sh-scrT98G or sh1 or sh2-PDE5 cells monolayers in the presence or absence 
of 1 μM sildenafil or 100 μM 8br-cGMP. C. Migration assay on matrigel cushions through transwell filters of sh-scr or sh1-PDE5 T98G 
cells in the presence or absence of 1 μM sildenafil or 100 μM 8br-cGMP. Scale bars= 50 μm. D. Histogram showing the relative migration 
capacity (fold increase ± SD) of cells that passed through the filter in the different treatments compared to control cells. E. Migration assay 
on matrigel cushions through transwell filters of mock- or PDE5-overexpressing U87MG (upper panels) or GBM line 83 cells (lower 
panels). Scale bar= 20 μm. F. Histogram showing the mean percentage ± SD of cells that passed through the filter. G. Histogram of the 
mean percentage ±SD of secreted MMP-2 in gelatin zymography (bottom image) in sh-scr or sh1-PDE5 T98G and H. in mock- or PDE5-
overexpressing U87MG cells and I. in sh-scr T98G stimulated with CNP, GSNO or sildenafil at the indicated concentrations. Data have 
been obtained from three independent experiments. (*p < 0.05; **p < 0.001).
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Figure 4: PKG expression and MYPT1 phosphorylation regulates GBM cells migration. A. PKG1 low and B. PKG1 high 
GBM samples, as revealed by immuno-histochemistry. Black arrows point to PKG1 expression within the vessel walls. White arrow points 
to tumor cells. Scale bar=20μm. C. Expression levels of PKGII, PKG1α and PKG1β and total PKG1 in sh-scr and sh1-PDE5 T98G cells 
and in wtT98G, U87MG, A172, LN18, 83 GBM lines. D. pVASP levels in sh-scr or sh1-PDE5 T98G cells before and after Y-27632 , 8br-
cGMP (50 μM) treatments. Representative image out of 4 independent experiments. E. Phosphorylation levels of MYPT1 (pSer695) in sh-
PDE5 or sh1-scr T98G upon the indicated treatments [8br-cGMP, 50 μM; Y-27632 (RI), 10 μM); KT5823 (PKGi), 2 μM]. F. Densitometric 
analysis of western blots from three independent experiments is shown. Bars represent the mean ±SD. G. sh-scr and sh1-PDE5 T98G 
invasion assays on matrigel cushions in the presence of Y-27632 or 8br-cGMP or both. H. Histogram showing the relative migration 
capacity (fold increase ± SD) of cells that reached the bottom of the matrigel cushion in the different treatments compared to control cells. 
(**p < 0.001).
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targeting subunit of myosin phosphatase (MYPT1), the 
regulatory subunit of myosin light chain phosphatase 
(MLCP) [31]. PKG-mediated phosphorylation of MYPT1 
blocks its subsequent inhibitory phosphorylation by 
Rho-kinase (ROCK) [32]. We found that pSer695 levels 
were increased in sh-PDE5 compared to sh-scr cells 
(Figure 4E) and in sh-scr cells treated with 100 μM 
8br-cGMP. Conversely, inhibition of PKG by KT5823 
reduced MYPT1 phosphorylation in cell treated with 8br-
cGMP (Figure 4E), suggesting that the effect elicited by 
knockdown of PDE5 was mediated by PKG. Although 
KT5823 activity in inhibiting PKG has been questioned in 
intact cells [33], we found that it was effective in glioma 
cells, as also reported by Charles et al. [23].
Next, PKG activity was indirectly evaluated from 
the levels of phosphorylation of the vasodilator-stimulated 
phosphoprotein (p-VASP). In line with the hypothesis, we 
found that 8br-cGMP treated sh-scr T98G and that sh-
PDE5 cells showed a stronger p-VASP band than sh-scr 
T98G cells, confirming that PKG activity was higher in 
these samples (Figure 4D). Since inhibition of the RHO/
ROCK complex components can promote mesenchymal 
cell migration pattern through the regulation of acto-
myosin contractility [34, 35], we treated sh-scr or sh-
PDE5 T98G cells with 10 μM Y-27632 (a ROCK inhibitor, 
RI). We observed that, while all sh-scr cells were on top of 
matrigel, ~70% of cells were migrated toward the bottom 
of the plate after 24 h of incubation in the presence of 
10 μM Y-27632 (Figure 4G-4H). In agreement with this 
observation, we found that ROCK inhibition induced 
a consistent increase of Ser695 p-MYPT1 levels in sh-
scr T98G cells, whereas combined treatment with 8br-
cGMP and Y-27632 did not increase it further (Figure 
4E-4F). Notably, we found that ROCK inhibition also 
increased the levels of VASP phosphorylation (Figure 4D), 
suggesting that ROCK negatively regulates PKG in GBM 
cells. Furthermore, while 8br-cGMP induced about 70% 
of sh-scr-T98G migration through the matrigel cushion, 
combined treatment with Y-27632 was able to induce 
100% of cell migration, suggesting that these agents 
synergistically promote GBM cell migration (Figure 4G-
4H). Since sh-PDE5 cells already migrated to the bottom 
of the plate, addition of 10 μM Y-27632 did not further 
increase the migration rate of these cells (Figure 4G-4H). 
These results suggest that PDE5 might regulateGBM 
cell contractility and migration by balancing the activity 
between PKG and ROCK on MYPT1phosphorylation as 
well as on other substrates.
PDE5 expression regulates sensitivity to ionizing 
radiations in GBM cell lines
Since all the patients analyzed in our study 
underwent radio- and chemotherapy treatments, the 
positive prognostic value of PDE5 expression may rely 
on the effect of this enzyme on GBM cells sensitivity to 
DNA-damaging agents. To test this hypothesis, sh-scr 
or sh1-PDE5 T98G and mock or PDE5 overexpressing 
U87MG cells were treated with X-ray doses from 2 to 6 
Gy. Cell survival was assessed by colony forming assays 
after 14d of culture. We found that knockdown of PDE5 
significantly increased the percentage of cells surviving 
to 2 to 4 Gy, while at 6 Gy few or no colonies were 
recovered from both cell types (Figure 5A). Conversely, 
PDE5-overexpressing U87MG cells showed a lower 
survival rate compared to mock-transduced cells exposed 
to radiation, even though the overall sensitivity to X-rays 
of U87MG was lower compared to T98G cells (Figure 
5B). To understand if the increased survival of GBM cell 
lines lacking PDE5 was due to increased DNA damage 
repair, the kinetics of γH2AX staining were monitored 
in irradiated cells. We found that more than 90% of cells 
showed intense γH2AX staining within their nuclei 4 h 
post irradiation, regardless of PDE5 expression. However, 
24 h post irradiation ~70% of sh-scr T98G cells showed 
nuclei containing more than 4 γH2AX positive foci/
cell compared to 30% of sh-PDE5 cells (Figure 6A). 
Furthermore, PDE5-overexpressing U87MG cell also 
showed much higher percentage of γH2AX positive 
nuclei compared to mock-infected cells (Figure 6B). 
These results suggest that PDE5 expression impairs DNA-
damage repair induced by ionizing radiations.
PDE5 levels regulate PARP activity
It has been recently reported that PDE5 inhibition 
protects hair cells and spiral ganglion neurons from 
sound-induced cell damage by increasing poly (ADP-
ribose) polymerase (PARP) activity [36]. To understand 
if a similar mechanism was activated in GBM cells, 
we evaluated the levels of protein poly(ADP-ribosyl)
ation (PARylation) in sh-scr and sh1-PDE5 T98G cells 
before and after different doses of X-ray exposure. In 
the absence of irradiation, sh1-PDE5 T98G cells showed 
higher protein PARylation levels (detected with the anti-
PAR antibody as a smear) and higher PARP-1 expression 
compared to sh-scr cells. Moreover, PARylation strongly 
increased following X-ray exposure and such increase was 
higher in sh-PDE5 compared to sh-scr T98G cells (Figure 
7A). Treatment with the PARP inhibitor olaparib (1 μM) 
strongly reduced PARylation in T98G (Figure 7B) and 
reduced sh-PDE5 cell viability after exposure to X-rays 
(not shown). These data indicate the involvement of PARP 
activity in radio-resistance of GBM cells and suggest 
that its pharmacological inhibition might counteract 
aggressiveness of PDE-negative GBM cells.
DISCUSSION
PDE5 finely regulates intracellular cGMP levels 
generated by GCs. These enzymes are directly activated 
by a range of ligands such as NO and natriuretic peptide 
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that bind s- or p-GC isoforms, respectively [37]. The 
role of the NO/GC/cGMP/PDE5 axis in tumor biology 
has been extensively studied, however its precise role 
has not been unequivocally established. Although 
genetic alterations of the PDE5 locus are relatively rare, 
increased PDE5 expression was shown to play a role in 
tumorigenesis in a variety of epithelial cancers [38, 39] 
and to be correlated with OS in breast cancer [40]. By 
contrast, PDE5 expression inversely correlates with tumor 
invasiveness in metastatic melanoma [19].
Our study first aimed at evaluating the association 
between PDE5 expression and clinical outcome in GBM 
patients. In three independent cohorts of GBM patients we 
found that high PDE5 protein and mRNA levels in GBM 
cells significantly associate with less aggressive cancer 
behavior and longer OS. Moreover, multivariate analysis 
identified PDE5 as a strong independent prognostic factor 
in GBM. Thus, our study indicates PDE5 expression as an 
important index of favorable prognosis in this disease. To 
elucidate the molecular mechanisms underlying the role of 
PDE5 in GBM, we genetically engineered GBM cell lines 
to stably express high or low levels of PDE5. Using these 
cell models, we unveiled two distinct roles of PDE5 in 
attenuating GBM aggressiveness: 1) decreased tumor cell 
invasion and migration via stabilization of acto-myosin 
interactions and decreased MMP-2 secretion; 2) enhanced 
radio-sensitivity by inhibiting DNA repair. The molecular 
players of NO/GC/cGMP/PDE5 axis were expressed in 
all the GBM cell lines analyzed and activation of this axis 
in T98G resulted in a significant increase of cGMP levels. 
The mechanisms underlying the reduced invasiveness 
of PDE5 expressing tumors correlated with low cGMP 
levels, as PDE5 silencing or 8br-cGMP treatment induced 
an invasive phenotype. Our data are in apparent contrast 
with recent reports describing a cytotoxic effect of PDE5 
inhibitors in in vitro treated brain cancer cell lines [16-
Figure 5: Effect of PDE5 on DNA repair and cell survival upon ionizing radiation. A. Left: survival curves of sh-scr (black 
squares) or sh1-PDE5 T98G cells (empty squares) exposed to increasing X-ray doses from 2 to 6 Gy. Right: representative images of 
clonogenic assays in untreated control cells or in cells exposed to 4 Gy. B. Left: survival curves of PDE5-overexpressing (black squares) 
or mock-expressing U87MG cells (empty squares) exposed to increasing X-ray doses from 2 to 6 Gy. Right: representative images of 
clonogenic assays in untreated control cells or in cells exposed to 4Gy.
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18, 41]. However, our in vitro studies confirmed that 
PDE5 inhibition or cGMP treatment acted to favour GBM 
aggressiveness and invasivity. Moreover, in line with our 
data, a role of cGMP in promoting murine and human 
melanoma cell growth and invasion has been recently 
reported [20], suggesting that PDE5 expression may play a 
protective role in cancer types of neuro-ectodermal origin.
Indeed, as in melanoma cells, ERK1/2 
phosphorylation was induced by increased cGMP 
levels, as it occurs following GSNO or CNP stimulation, 
suggesting that migration of stimulated cells could in 
part be mediated by the increase of MAPK activity. High 
cGMP levels induced phosphorylation of MYPT1 at 
Ser695, an event that decreases actin/myosin interactions 
and promotes relaxation and forward motility in 
fibroblasts [42]. Although migrating cells activate Rho 
GTPases to control myosin phosphorylation and cell 
motility, they also control GC activity and cGMP increase 
[43]. Indeed, GBM invasiveness has been shown to 
be strongly induced by negative regulation of ROCK2 
activity [44–46]. We demonstrated that ROCK inhibition 
increased GBM invasiveness and increased Ser695 
MYPT1 levels, similarly to what has been described for 
rat neuronal migration [47]. Although ROCK inhibition 
Figure 6: Effect of PDE5 expression on γ-H2AX foci induced by X-ray treatment. A. Left: counts of nuclei containing ≥ 
4 γ-H2AX foci in sh-scr or sh-PDE5 T98G cells; right representative immunofluorescence images of γ-H2AX foci. B. Left: counts of 
nuclei containing ≥ 4 γ-H2AX foci in mock- or PDE5-overexpressing U87MG cells; Right: representative immunofluorescence images of 
γ-H2AX foci. Cells were immunostained for γ-H2AX after 24 h at 4 Gy irradiation. (*p < 0.05; **p < 0.001). Bar= 10 μm.
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and 8br-cGMP stimulation synergistically increased 
matrix invasion, Ser695 p-MYPT1 levels did not further 
increase, suggesting that MYPT1 phosphorylation was 
not the only event following ROCK inhibition or PKG 
activation leading to the control cancer cell migration. 
In line with these findings, PKG activation was shown 
to promote breast cancer cell invasion via caldesmon 
phosphorylation and inhibition of actin/myosin 
interactions [48]. The decreased invasiveness of PDE5-
overexpressing GBM cells was associated with lower 
MMP-2 levels, while cGMP elevating agents such as 
GSNO, CNP or sildenafil up-regulated MMP-2 secretion 
in T98G cells, as previously shown in synovial cells, 
colon cancer cells and NO-stimulated murine mammary 
adenocarcinoma cells [49, 50]. The finding that sildenafil 
alone increased MMP-2 secretion by T98G cells after 
an overnight incubation is in line with its effects on 
glioblastoma cell migration and is similar to the effects 
induced by PDE5 silencing, suggesting that continuous 
PDE5 inhibition might stimulate GC activity in tumor 
cells, as it was shown by the increase of cGMP levels. 
Our results suggest that GBM cell invasiveness can be 
modulated by PDE5 expression and ROCK activity that, 
by inhibiting PKG, controls cytoskeletal interactions 
and extracellular matrix remodeling. Indeed, PKG1 was 
found to be expressed in all the GBM samples, although 
Figure 7: PDE5 knockdown increases PARP1 activity in GBM cells. A. sh-scr (PDE5+) or sh1-PDE5 (PDE5-) T98G cells were 
treated with increasing X-ray doses from 2 to 4 Gy and probed with anti-PAR and anti-PARP-1 antibodies. B. sh-scr or sh1-PDE5 T98G 
cells were exposed to X-rays at 4 Gy in the presence or absence (+/-) of the PARP1 inhibitor olaparib (1 μM). Total protein PARylation 
levels were assayed after 24 h. C. Schematic representation of cGMP signaling pathway promoting migration and DNA repair in GBM 
cells.
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at different levels, suggesting that NO/GC/PKG pathway 
activation can act on tumors to promote aggressive 
potential. PDE5-expressing GBM cells showed defective 
DNA repair activity and reduced cell survival to irradiation 
compared to PDE5-low or -negative cells. Moreover, high 
cGMP levels induced resistance to DNA damaging agents 
through increased DNA repair proficiency (see Figure 7C). 
Since all the GBM patients in our study also underwent 
radio- and chemotherapy, our results strongly suggest 
that the increased OS observed in high PDE5 patients 
is linked to enhanced sensitivity of GBM cells to DNA 
damage. The increased repair mechanism in sh-PDE5 
cells correlated with increased PARP-1 activity and this 
effect was reversed by the presence of the PARP inhibitor 
olaparib. In agreement with these results a previous 
report demonstrated that activation of cGMP-PKGI 
signaling pathway through PDE5 inhibition culminates in 
the activation of PARP-1 in hair cells and in the spiral 
ganglion [36].
In conclusion, our results indicate that PDE5 
expression lowers the invasive potential and DNA repair 
ability of GBM cells, explaining the poor survival in 
PDE5-low GBM patients. Stratification of GBM into 
PDE5-low and -high expression groups may allow 
identification of tumors that are more invasive and 
resistant to ionizing radiations. This implies that PDE5-
negative GBM patients could be predicted to be resistant 
to radiotherapy and preferably enrolled in alternative 
therapeutic procedures, such as combined treatment with 
PARP inhibitors.
PDE5 inhibitors (PDE5i) have been proposed to 
enhance anti-tumor efficacy of chemotherapeutic agents 
by increasing permeability of the brain blood barrier [17]. 
Potential PDE5i therapies would then be applicable only 
to PDE5-negative GBMs, that would be insensitive to 
these drugs, but not to PDE5-positive GBMs. Moreover, 
the use of PDE5i in erectile dysfunction as well as in 
pulmonary hypertension should be evaluated in PDE5 
positive GBM patients. We propose PDE5 as a highly 
statistically significant prognostic marker of increased OS 
in GBM patients and identify PKG, ROCK and PARP1 
as potential therapeutic targets for this subset of brain 
cancers.
MATERIALS AND METHODS
Sixty-nine tumor tissue samples were collected at 
surgery from patients who underwent craniotomy for 
complete or partial resection of GBM at the Institute 
of Neurosurgery, Catholic University School of 
Medicine, in Rome. Patients were eligible for the study 
if a diagnosis of GBM was established histologically 
by the neuropathologist in accordance with the WHO 
classification [2]. The patients were 27 to 80 year old 
at the time of diagnosis (median age, 62 yrs); 45 were 
men and 24 were women. In all cases, the tumor samples 
were obtained by resection before treatment with 
radiation and TMZ. Thirteen out 69 patients (18,8%) 
underwent to subtotal tumor resection. After surgery, the 
patients received radiotherapy to limited fields (2 Gy per 
fraction, once a day, 5 days a week, 60 Gy total dose) 
and concomitant TMZ (75 mg per square meter of body 
surface area per day) for 7 days a week from the first 
to the last day of radiotherapy followed by six cycles of 
adjuvant TMZ (at 150-200 mg per square meter of body 
surface area on days 1 to 5) given at 4 week intervals. 
Survival was calculated from the date of surgery when 
a diagnosis of GBM had been established. The disease 
was considered to have progressed if the sum of products 
of perpendicular diameters of any enhancing lesion 
increased by 25% of initial measurements, if a new lesion 
was evident on axial contrast-enhanced T1-weighted 
magnetic resonance imaging scan, or if the patient’s 
neurologic condition worsened and required an increased 
dose of steroids [51]. Only those patients who completed 
radiation therapy and concomitant TMZ were included. 
Patients who died during cycles of adjuvant TMZ were 
included. Immunohistochemical patterns were assessed 
as previously reported [52, 53]. The Ki-67 (1:1000, MIB-
1, Dako, Milan, Italy) labeling index was defined as the 
percentage of positive nuclei of a total of 2000 tumor 
cells counted using an eyepiece grid. The positive nuclei 
were counted by 2 pathologists (L.M.L. and M.M.). In 
order to minimize contamination by normal cells, the 
tumor areas dissected for DNA and mRNA extraction 
contained at least 80% of tumor cells. Expression of 
EGFRVIII was performed as previously described 
[9]. The O(6)-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation patterns were studied 
by methylation-specific PCR using primers specific for 
methylated and unmethylated DNA on genomic DNA 
extracted from paraffin-embedded tissue (QIAmp DNA 
Mini kit, Qiagen, Milan, Italy) [54]. The annealing 
temperature was 60°C. DNA from normal lymphocytes 
treated or untreated with SssI methyltransferase (New 
England Biolabs, Ipswich, MA, USA) was obtained 
for positive and negative controls, respectively. PCR 
products were separated onto 3% agarose gel, stained 
with ethidium bromide, and visualized under UV 
illumination.
For mRNA expression data, we used the publicly 
available data sets: GSE2221 [55] or in [24, 25]. The data 
sets were analyzed by the Oncomine platform [26].
RT-PCR
Total RNA from the different cell lines was extracted 
with Trizol reagent and treated with DNase I to avoid 
potential contamination by genomic DNA. DNA-free 
RNA was reverse transcribed using Bioline (BIO-65043) 
tetro cDNA Synthesis Kit according to the manufacturer’s 
instructions.
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For semi quantitative RT-PCR 25 cycles 
were performed for the amplification of Actin, 
35 cycles for for all the others. Primers for 
cDNA amplification were: GUCY1A2 for 
5’GGTTACAGGGATGCAGAAAAGAAT3’; rev 5’TTCA 
GGGAGCTCTTTGCATAGG3’. NPR2 for 5’ACCATTAT 
CGTACCCTGGTT3’, rev 5’ TCTCGGTACGTGATCAC 
CAATA3’. PDE1A for 5’AGCAATGGTCTTTGCTGCTG; 
rev 5’AGTCGATAAGCTGCACTCAC. PDE3A for 5’CGT 
CACCTTCGCTAGTGAAA; rev 5’AACTCGTCTCAACA 
AGCCAG. ACTIN for 5’GCGAGAAGATGACCCA 
GATCA ; rev 5’CACAGGACTCCATGCCCAGGA. 
GUCY1B3 for 5’ GAGGAGTACAVACTAGGTTCCAGT; 
GUCY1B3 rev 5’ CACATGAAGCTCACATCATC; 
GUCY1A3 for AGACAGTAGACCTTCTGTGCTC; 
GUCY1A3 rev TCCACCTTGTAGACATCCAG.
Statistical analysis
OS obtained from patients herein analyzed was 
calculated from the date of surgery when a diagnosis 
of GBM was established, to death from any cause. 
Progression-free survival (PFS) was determined from 
the date of surgery until progression or death. Survival 
curves were plotted using the Kaplan-Meier method 
and differences between groups were evaluated using 
the log-rank test. Multivariate analysis for survival was 
performed by using the Cox proportional hazards model 
to control for age, Karnofsky performance status (KPS), 
Ki67 measurement values, MGMT promoter methylation, 
expression of EGFRvIII, surgical resection (subtotal or 
total) and PDE5A expression. Continuous variables not 
normally distributed are reported as median and 95% 
CI. Comparison of continuous variables not normally 
distributed was performed using the Mann-Whitney 
U test; continuous variables normally distributed 
are reported as mean and standard deviation (SD). 
Comparison of continuous variables normally distributed 
was performed using the Student’s t test. Comparison 
of categorical variables between the two groups was 
performed by the Chi-square statistic, or using the Fisher 
exact test when appropriate. All p-values are based 
on Student’s t two-tailed tests and differences were 
considered statistically significant when p<0.05. Asterisks 
indicate the level of statistical significance (*p < 0.05; 
**p < 0.001).
OS obtained from GEO dataset ID: GSE13041 
[25] was evaluated by using Kaplan-Meier analysis and 
Cox proportional hazard regression model. Samples 
were sorted by the intensity level and divided in two 
subgroups (high intensity level, low intensity level). 
Approximately the same amount of samples were 
used for comparison in the two groups where the 
difference in the signal level was wider (high intensity 
vs low intensity). The log-rank test was used to evaluate 
differences between curves.
Immunohistochemistry for PDE5A, PKG1 
and SMA
Formalin-fixed, paraffin embedded sections (4μm 
thick) were mounted on positive charged glass slides. 
For PDE5A and PKG detection, deparaffinized and 
rehydrated sections were retrieved in TE solution (pH 9). 
Endogenous peroxidase was blocked (ScyTek, Logan, 
UT) and then sections were incubated for 1h at room 
temperature with rabbit polyclonal antibody anti-PDE5A 
(1:100 diluition, H-120, sc 32884; Santa Cruz Biotech, 
Heidelberg, Germany) or with rabbit polyclonal anti-PKG 
(1:100 dilution, ADI-KAP-PK005; Enzo Life Sciences, 
Italy) followed by the avidin-biotin-peroxidase complex 
method (UltraTek HRP Anti-polyvalent, ScyTek). 3,3’ 
diaminobenzidine was used as the enzyme substrate to 
observe the specific antibody localization, and Mayer 
hematoxylin was used as a nuclear counterstain. Normal 
central nervous system biopsies were used as internal 
control. Tumor sections stained in the absence of the 
primary antibody were used as negative controls. For SMA 
staining, tissue sections were incubated with anti-α-smooth 
muscle actin-FITC (clone 1A4, Sigma-Aldrich, 1:100) and 
nuclei counterstained with Hoechst. Immunofluorescence 
was evaluated by epifluorescence using Leica CTR6000 
microscope. All samples were stained more than once and 
the results were highly reproducible.
Cell culture, proliferation and viability assays
The GBM cell lines (T98G, U87MG, A172, 
U251, LN18) used in this study were grown in DMEM, 
(Euroclone; Milan, Italy) with 10% fetal bovine serum 
(FBS) (Euroclone). T98G and U87MG cell proliferation 
was tested using 3H-thymidine incorporation assay 
[56] and cell viability was tested by MTS colorimetric 
assay (Promega, Milan, Italy). Glioblastoma stem cell 
line 83 was derived from patient derived glioblastoma 
obtained after informed consent and surgery, validated 
and grown in stem cell medium as previously reported 
[57]. The MAPK inhibitors PD98059 and U0126 were 
from Calbiochem (Milan, Italy). hEGF and hbFGF 
were from Immunological Sciences (Rome, Italy). 
Olaparib was obtained from Selleckchem (Milan, Italy). 
S-nitrosoglutathione (GSNO, a synthetic nitric oxide 
donor) and type C natriuretic peptide (CNP) were from 
Sigma-Aldrich (Milan, Italy).
Migration and invasion assays
For wound healing assays, 1x105 cells per well 
were seeded in 24-well culture plates to obtain a confluent 
monolayer. Confluent monolayers were then scored with a 
sterile pipette tip to make a scratch of approximately 0.4–
0.5 mm in width. Culture medium with any dislodged cells 
was then removed and cells were treated with sildenafil or 
8br-cGMP (a non-hydrolysable cell-permeable analog of 
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cGMP) (Sigma-Aldrich). Cells were allowed to migrate 
through the scratched area for 24 hours. Cell migration 
was visualized using Leica CTR6000 microscope. The 
wound area was measured by the program Image J 
software (NIH, Bethesda, MD). The percentage of wound 
closure was estimated by the following equation: wound 
closure % = [1 − (wound area at Tt/wound area at To)]
x100%, where Tt is the time after wounding and To is 
the time immediately after wounding. Three independent 
experiments were performed. The in vitro cancer cell 
invasion assays were performed in 24-well transwell 
insert with 8μm pore size coated with 50 μL matrigel 
(Corning Life Sciences, Sigma-Aldrich). Two × 104 cells 
were added to the upper chamber in 0.2 mL serum-free 
medium; the bottom chamber contained medium with 10% 
FBS which acted as cell attractant. For migration of GBM 
line 83, cells were directly seeded on top of matrigel in 
serum free medium and the bottom chamber contained 10 
ng/ml bFGF and 10 ng/ml EGF supplemented medium. 
After 24 hours incubation, cells that reached the underside 
of the filter were stained with Hoechst 3342 dye (Sigma-
Aldrich) and counted for Hoechst or EGFP fluorescence by 
fluorescent microscopy based on five-field digital images 
taken randomly at 200× magnification. Three independent 
experiments were performed. In some experiments we 
modified the transwell invasion assay by seeding 103 cells 
in serum free medium on top of a 50 μl matrigel cushion 
in 96 well chambers. After 24 h, the ratio of the number of 
cells at the bottom of the well on the total number of cells 
was obtained.
Colony assay after DNA damaging treatments
For irradiation experiments, exponentially 
growing sh1-PDE5 and sh-scr T98G or mock and 
PDE5 overexpressing U87MG cells were seeded at 20/
cm2 density and exposed to 2,4,6 Gy dose of acute 
137Cs gamma irradiation, at a dose rate of 0.8 Gy/min 
(Gammacell 40 Exactor Best Theratronics at the ISS, 
Rome, Italy). To follow recovery after DNA damage, cells 
were then incubated at 37°C for 14 days (T98G cells) or 
21 days (U87MG cells).
Surviving colonies were fixed with 100% methanol 
and then stained with Giemsa staining (Sigma-Aldrich) for 
1 hour. Colonies ≥0.5 mm in diameter, were counted using 
a light microscope (Nikon, Milan, Italy). Four independent 
experiments were performed for each treatment.
Immunofluorescence analysis
Cells grown on glass coverslips after mock or 4-Gy 
irradiation were fixed with 4% paraformaldehyde and 
incubated with rabbit anti-γ-H2AX antibody (Millipore, 
Milan, Italy) and Alexa Fluor® 594-conjugated secondary 
antibody (Thermofisher, Milan, Italy). T98G grown on 
glass coverslips were also incubated in anti PDE5 antibody 
and in Alexa Fluor® 594-conjugated secondary antibody. 
U87MG cells were used to validate anti-PDE5 antibody 
specificity (not shown). Nuclei were counterstained with 
Hoechst 33349. For each sample >200 cells, containing 
four or more γ-H2AX foci/nucleus, were scored as 
positive. Three independent experiments were performed 
was performed on T98G.
List of WB antibodies
Anti-tubulin mouse monoclonal (A2066, Sigma-
Aldrich 1:1000), anti PKGIα goat polyclonal (1:1000,N-
16, sc10335 Santacruz Biotech), anti-PKGIβ goat 
polyclonal (1:1000, L-16, sc10341), anti PKGII (1:1000, 
T-10, sc10346, goat polyclonal, SantaCruz Biotech), 
anti pSer239-VASP mouse monoclonal (1:1000, 16C2, 
sc101439, SantaCruz Biotech), anti p- MYPT1 (Ser695) 
rabbit polyclonal (1:1000, A-6, sc-33360 Santacruz 
Biotech), anti-PAR mouse monoclonal (1:1000, Trevigen, 
Gaithersburg, MD, USA), anti-PARP-1 rabbit polyclonal 
(1:1000, SantaCruz Biotech), anti PDE1C rabbit 
polyclonal (1:1000 Fabgennix, TX, USA). Densitometric 
analyses of western blots were performed by ImageJ 
(http://rsb.info.nih.gov/ij/index.html).
Lentiviral vector production and transduction
Lentiviral PDE5 silencing vectors [RHS4430-
101103886 Clone V3LHS_325328 (silencing sequence: 
CGGTTAATGCAGAAGTTG) sh1PDE5] and lentiviral 
scrambled control [RHS2349] were purchased from 
Dharmacon (Milan,Italy). Another PDE5 ORF region was 
chosen to prepare a second sh-lentiviral construct (sh2) 
using cagaagaatggtacaaatcca as silencing sequence and 
cloned in pLKO plasmid (EcoRI-AgeI) (Addgene). For 
PDE5 overexpression human PDE5 A1 ORF was cloned 
into pRRLsin.PPT.CMV.NTRiresGFPpre lentiviral vector 
in the Xba5’-Xho3’ sites. All the lentiviral particles were 
obtained in Hek293T cells [58] and supernatant was 
concentrated by ultracentrifugation at 28,000 rpm for 2 h 
at 4°C. Cells were infected at MOI 10 and stable pools of 
cells were selected with 5 μg/mL puromycin.
Gelatin zymography analysis
Conditioned media from sh1-PDE5, sh-scr T98G or 
from mock and PDE5 overexpressing U87MG cells at 72 
hours of culture were used for the detection of MMP-2 and 
MMP-9 by gelatin zymography analysis as described in 
[59]. Conditioned media from sh-scr T98G, sh-scr T98G 
stimulated with GSNO, with CNP or with sildenafil were 
collected after 24h of stimulation. Quantification of MMP-
2 and MMP-9 and western blot bands were achieved after 
image capture and by computerized image analysis using 
image J software. The secretion of MMP-2 in mock-
treated cells was taken as 100%. Three independent 
experiments were performed.
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cGMP measurement
The cGMP levels in the glioblastoma cell lines 
were measured using an ELISA kit according to the 
manufacturer’s instructions (ADI-900-014, Enzo Life 
Sciences, Italy). cGMP concentration was normalized per 
mg of total proteins.
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